The Waldenstrom macroglobulinemia market is expected to witness steady growth, driven by increasing disease awareness, improvements in diagnostic capabilities, and the continued development of targeted therapies. The adoption of novel treatment approaches, including BTK inhibitors, proteasome inhibitors, immunotherapies, and emerging next-generation targeted agents including Iopofosine I-131 (Cellectar Biosciences), Nemtabrutinib (MK-1026-003; Merck Sharp & Dohme), Sonrotoclax (BeOne), TT-01488 (TransThera Biosciences), and others, is expanding treatment options for patients with Waldenstrom macroglobulinemia.

LAS VEGAS, Sept. 9, 2026 /PRNewswire/ -- Recently published Waldenstrom Macroglobulinemia Market Insights report includes a comprehensive understanding of current treatment practices, Waldenstrom macroglobulinemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Waldenstrom Macroglobulinemia Market Summary

- The total Waldenstrom macroglobulinemia treatment market size is expected to grow positively by 2036 in the leading markets.

- The United States accounted for the largest Waldenstrom macroglobulinemia treatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

- Waldenstrom macroglobulinemia has an incidence rate of approximately 3 cases per million annually in the US, with 1,000 to 1,500 new diagnoses each year.

- Leading Waldenstrom macroglobulinemia companies, such as Cellectar Biosciences, Merck Sharp & Dohme, BeOne, TransThera Biosciences, NURIX, Schrödinger, Inc., Ascentage Pharma, ADC Therapeutics, and others, are developing new Waldenstrom macroglobulinemia treatment drugs that can be available in the Waldenstrom macroglobulinemia market in the coming years.

- The promising Waldenstrom macroglobulinemia therapies in clinical trials include Iopofosine I-131, Nemtabrutinib (MK-1026-003), Sonrotoclax, TT-01488, Bexobrutideg (NX-5948), SGR-1505, Lisaftoclax (APG-2575), Loncastuximab tesirine (Lonca), and others.

Discover Waldenstrom macroglobulinemia clinical trial 2026 update press release @ https://www.delveinsight.com/report-store/waldenstrom-macroglobulinemia-market

Key Factors Driving the Growth of the Waldenstrom Macroglobulinemia Market

- Increasing Prevalence of Waldenstrom Macroglobulinemia: Although Waldenstrom macroglobulinemia remains a rare hematological malignancy, the number of diagnosed patients is expected to increase as populations age and disease recognition improves. The predominantly older patient population represents an important factor supporting long-term market demand.

- Growing Disease Awareness and Diagnosis: Increasing awareness of Waldenstrom macroglobulinemia among healthcare professionals is supporting earlier recognition and diagnosis. Improved access to hematological testing and advanced diagnostic techniques is also helping identify previously undiagnosed patients.

- Rising Adoption of Targeted Therapies: The introduction and broader use of targeted treatments, particularly BTKis, have transformed the WM treatment landscape. Their efficacy, oral administration, and more favorable tolerability compared with traditional chemotherapy are driving treatment adoption.

- Advances in Molecular and Genetic Understanding: Greater understanding of molecular alterations, including MYD88 and CXCR4 mutations, is facilitating more precise disease characterization and therapeutic development. These advances are supporting biomarker-driven treatment strategies and the development of novel targeted therapies.

- Robust Pipeline of Novel Targeted Agents: The expanding pipeline of BTK degraders, non-covalent BTK inhibitors, BCL-2 inhibitors, and targeted radiotherapeutic agents is anticipated to broaden the treatment landscape. These novel therapies may help overcome resistance mechanisms and enhance clinical outcomes for patients with relapsed or refractory disease.

Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that nemtabrutinib is expected to achieve meaningful uptake following potential approval, particularly in R/R patients who have progressed on covalent BTK inhibitors. Bexobrutideg may establish a differentiated position through its BTK degradation mechanism, which could help overcome resistance-associated mutations and support adoption in heavily pretreated patients.

Waldenstrom Macroglobulinemia Market Analysis

- The treatment landscape for Waldenström macroglobulinemia has evolved considerably over the past decade, largely driven by the emergence of Bruton's tyrosine kinase inhibitors.

- Before the advent of targeted therapies, treatment primarily centered on rituximab-based immunochemotherapy regimens, which were often associated with substantial treatment-related toxicities.

- The approval of ibrutinib (IMBRUVICA) in 2015 represented a major milestone in the management of Waldenström macroglobulinemia, as it became the first therapy specifically approved for the disease and established BTK inhibition as a key component of treatment.

- Subsequently, zanubrutinib has emerged as a strong competitor, supported by favorable efficacy and tolerability outcomes demonstrated in the ASPEN trial. Although IMBRUVICA continues to generate significant global revenue, its sales have declined from previous levels amid increasing competition from next-generation BTKi, particularly zanubrutinib.

- With its expanding adoption across B-cell malignancies globally, zanubrutinib is expected to capture a growing share of the Waldenström macroglobulinemia market over the forecast period.

- The emerging pipeline is also expected to further diversify treatment options for relapsed/refractory (R/R) disease.

- Nemtabrutinib (MK-1026-003) has demonstrated encouraging clinical activity in patients previously treated with covalent BTK inhibitors, potentially positioning it as an important therapeutic option in the R/R setting.

- Bexobrutideg (NX-5948), a next-generation BTK degrader, employs a differentiated mechanism by targeting both wild-type and mutant BTK proteins, potentially addressing acquired resistance to conventional BTK inhibitors.

- Additionally, pending potential FDA approval, iopofosine could offer a meaningful treatment option for patients with R/R disease, particularly given the estimated ~11,500 R/R patients and ~1,000 patients who exhaust available treatment options by the third-line setting in the US.

- Overall, the Waldenström macroglobulinemia market across the 7MM is anticipated to experience steady growth through 2036.

- Market expansion is expected to be supported by rising diagnosis rates, improved patient survival, increasing adoption of targeted therapies, and continued innovation in the treatment of B-cell malignancies.

- These developments are likely to create substantial commercial opportunities for both established therapies and emerging pipeline agents over the forecast period.

Waldenstrom Macroglobulinemia Competitive Landscape

Some of the Waldenstrom macroglobulinemia drugs under development include Iopofosine I-131 (Cellectar Biosciences), Nemtabrutinib (MK-1026-003; Merck Sharp & Dohme), Sonrotoclax (BeOne), TT-01488 (TransThera Biosciences), Bexobrutideg (NX-5948; NURIX), SGR-1505 (Schrödinger, Inc.), Lisaftoclax (APG-2575; Ascentage Pharma), Loncastuximab tesirine (Lonca; ADC Therapeutics), and others.

Iopofosine I-131 is Cellectar's lead investigational phospholipid drug conjugate (PDC) radiotherapeutic, developed to selectively deliver iodine-131 to tumor cells while limiting radiation exposure to healthy tissues. The therapy has been evaluated in the completed CLOVER-WaM Phase II pivotal study in patients with relapsed/refractory (R/R) Waldenström macroglobulinemia. Iopofosine I-131 has also received multiple regulatory designations in the US and EU for Waldenström macroglobulinemia, including Orphan Drug Designation (ODD) in both regions, as well as Breakthrough Therapy Designation (BTD) and Fast Track Designation (FTD) in the US and PRIME Designation in the EU.

Merck Sharp & Dohme's Nemtabrutinib (MK-1026, formerly ARQ 531) is an investigational oral, non-covalent and reversible Bruton's tyrosine kinase inhibitor (BTKi) being developed by Merck Sharp & Dohme for the treatment of multiple B-cell malignancies, including relapsed/refractory Waldenström macroglobulinemia.

BeOne's Sonrotoclax is an orally active small-molecule inhibitor of B-cell lymphoma-2 (BCL2) and belongs to the BH3 mimetic class. Compared with venetoclax, sonrotoclax demonstrates greater selectivity and enhanced pharmacological potency against BCL2. Its shorter half-life and lack of drug accumulation may also offer greater dosing convenience and improved treatment flexibility for patients.

NURIX's NX-5948 is an orally administered, CNS-penetrating small-molecule degrader targeting Bruton's tyrosine kinase (BTK), currently under investigation for the treatment of chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), and Waldenström macroglobulinemia (WM).

The anticipated launch of these emerging therapies are poised to transform the Waldenstrom macroglobulinemia market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the Waldenstrom macroglobulinemia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about the latest treatments for Waldenstrom macroglobulinemia 2026 @ Waldenstrom Macroglobulinemia Therapeutics Clinical Trials

Recent Developments in the Waldenstrom Macroglobulinemia Market

- In June 2026, Cellectar Biosciences, Inc.